ETASCAI Pilot Project

Launched by UNIVERSITY OF READING · Jan 23, 2025

Keywords

ClinConnect Summary

The ETASCAI Pilot Project is a clinical trial aimed at understanding how a product called ETAS® affects thinking, mood, and inflammation in healthy adults aged 60 to 80 years who have some mild to moderate concerns about their memory. This study is currently looking for participants to join, and they will be closely monitored to see how ETAS® might help improve their overall brain health and well-being.

To be eligible for this trial, participants should be between 60 and 80 years old, have normal vision and hearing, and have a healthy weight. They should also experience some mild to moderate memory complaints. However, certain conditions would exclude individuals from participating, such as having serious mental health issues, specific medical diseases, or taking certain medications. If you decide to participate, you'll be providing valuable information that could help improve understanding of cognitive health in older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aging between 60-80 years old
• • Having normal vision and hearing
• • Having a body mass index between 18.5 and 30
• • Having mild to moderate subjective cognitive complaints
• Exclusion Criteria:
• • Smoking
• • Having food allergies or intolerances
• • Following restrictive and/or unbalanced diets
• • Changing dietary intake majorly in past month
• • Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders
• • Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or suffering from hypertension or thrombosis related disorders or suffer from thyroid disease
• • Being anaemic
• • Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors
• • Currently consuming prebiotic or probiotic supplements
• • Continuous antibiotic use for \> 3 days within 1 month prior to enrolment
• • Continuous use of weight-loss drug for \> 1 month before screening
• • Having inflammatory bowel disease; coeliac disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years